Lilly migraine drug on PBS doorstep

By Megan Brodie 3 years ago | In Products, Regulatory
  • 3 years ago

7 April 2021 Eli Lilly’s controversial new migraine drug EMGALITY (galcanezumab) leapfrogged into government processes…

This is subscriber-only content. Please login to continue reading.